Loading data for ADPT — first visit, this takes a few seconds.

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS: ADPT · Real-Time Price · USD

24.34

-0.58 (-2.33%)

At close: Sep 02, 2026, 7:01 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	17.67
Market Cap	3.95B
Revenue (ttm)	308M
Net Income (ttm)	-63.9M
	2.09
	-0.4
	n/a
	-134.03
P/B (ttm)	27.57
P/S (ttm)	12.83
Earnings Date	Nov 4, 2026

Ask	31.37
Volume	1,619,998
Avg. Volume (20D)	2,964,264
Open	24.91
Previous Close	24.92
Day's Range	24.20 - 25.11
52-Week Range	12.00 - 26.87
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining num...

[Read more]

Industry Diagnostics & Research

Sector Healthcare

IPO Date Jun 27, 2019

Employees 624

Stock Exchange NasdaqGS

Ticker Symbol ADPT

Website https://www.adaptivebiotech.com

Full Company Profile

Financial Performance

In 2025, Adaptive Biotechnologies's revenue was 276.98M, an increase of 54.77% compared to the previous year's 178.96M. Earnings were -59.5M, a decrease of -62.69%.

Financial Statements

Earnings Surprise

Adaptive Biotechnologies has released their quarterly earnings on Jul 29, 2026:

Revenue of n/a misses estimates by $0, with -100.00% YoY decline.
EPS of -0.25 misses estimates by -0.12, with -47.06% YoY decline.

Next Earnings Release

Adaptive Biotechnologies Corporation is scheduled to release its earnings on Nov 4, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 week ago · Trefis

What Is Really Moving Tempus AI Stock Right Now?

While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.

1 week ago · Barchart

Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.

Adaptive Biotechnologies (ADPT) has surged 100% over the past year, driven by strong technical momentum. Shares recently hit a new 3-year high. Analyst sentiment is mixed with price targets ranging fr...

1 month ago · GuruFocus.com

Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.

1 month ago · Zacks

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key m...

1 month ago · Zacks

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

Page 1 of 2

Adaptive Biotechnologies Corporation (ADPT)